Open AccessPharmacotherapy for liposarcoma: current and emerging synthetic treatments
Author(s) -
Florence Chamberlain,
Charlotte Benson,
Khin Thway,
Paul H. Huang,
Robin L. Jones,
Spyridon Gennatas
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1092
Subject(s) - eribulin , liposarcoma , medicine , trabectedin , soft tissue sarcoma , dacarbazine , oncology , doxorubicin , chemotherapy , sarcoma , pathology , cancer , breast cancer , metastatic breast cancer
Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15–20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable chemosensitivity according to subtype. Decisions regarding management should be made on an individual basis, but surgery for localized disease and systemic chemotherapy remain the mainstay of treatment. Currently, only doxorubicin and trabectedin have robust Phase III data to support their use in the management of advanced liposarcoma. However, in the subgroup analysis of a Phase III trial comparing eribulin with dacarbazine, there was a greater than 7-month improvement in median overall survival in those treated with eribulin. There are also promising results from emerging studies in novel and targeted agents for the treatment of liposarcoma.